Nonalcoholic fatty liver disease (NAFLD) remains the prime prevalent cause of chronic liver disease globally, which is strongly related to obesity and insulin resistance.

Recent Findings have shown that-

• Significant weight loss tends to improve NAFLD and nonalcoholic steatohepatitis (NASH). 
• Diet and exercise that result in a sustained bodyweight reduction of 7–10% can improve liver fat content, NASH, and fibrosis. 
• Vitamin E can be considered in patients with biopsy-proven NASH without diabetes; however, it must be cautiously used in patients with prostate cancer.
• Pioglitazone can be administered in patients with or without diabetes for improving liver histology, including fibrosis. 
• Glucagon-like peptide-1 (GLP-1) antagonists still demand more investigations before they can be recommended in patients with NASH.
• Bariatric surgery, with resultant weight loss, can improve liver fat and inflammation.
• Improvement in liver fat content, liver inflammation and fibrosis remains the goal of the treatment.

Source- Curr Obes Rep 2019;8: 220–228. https://doi.org/10.1007/s13679-019-00345-1